Joan Vidal-Jove1, Eloi Perich2, Manuel Alvarez Del Castillo3. 1. Surgical Oncology HIFU Unit, Hospital Universitari Mutua Terrassa (HUMT), Pl. Dr. Robert, 5, 08221 Terrassa, Barcelona, Spain. Electronic address: http://www.mutuaterrassa.cat. 2. Surgical Oncology HIFU Unit, Hospital Universitari Mutua Terrassa (HUMT), Pl. Dr. Robert, 5, 08221 Terrassa, Barcelona, Spain. 3. Medical Direction Departments, Hospital Universitari Mutua Terrassa (HUMT), Pl. Dr. Robert, 5, 08221 Terrassa, Barcelona, Spain.
Abstract
UNLABELLED: We described the experience of the HIFU Onco Unit of Hospital University Mutua Terrassa (Barcelona, Spain) treating malignant tumors, focusing on results of unresectable pancreatic tumors treated with Ultrasound Guided High Intensity Focused Ultrasound (USgHIFU) hyperthermia ablation in combination with adjuvant chemotherapy. MATERIALS AND METHODS: From February 2008 to December 2013, we treated 140 malignant cases. Of those, 48 cases of unresectable pancreatic tumors were treated from March 2010 to December 2013, and the first 43 were included in the analysis. All the 43 cases (29 cases of stage III and 14 cases of stage IV) were treated with systemic chemotherapy. Clinical responses (thermical ablation achieved) were measured by image techniques, and complications were also recorded and analyzed. RESULTS: The majority of the 140 cases treated at our HIFU center were pancreatic and liver tumors, among which 43 cases of pancreatic tumors were analyzed. Clinical responses (ablation obtained) were observed in 82% of the cases, and the responses lasted at 8 weeks post-procedure. We obtained 11 complete responses (25%) at the end of the combined treatment, nine from stage III patients and two from stage IV patients. Major complications included severe pancreatitis with GI bleeding (1), and skin burning of grade III that required plastic surgery (2). The median survival was 13 months (6 months-2.7 years). No deaths were registered during the course of the treatment. CONCLUSIONS: HIFU is a potentially effective and safe modality for the treatment of malignant tumors. HIFU proves to have a survival advantage in treating unresectable pancreatic cancer.
UNLABELLED: We described the experience of the HIFU Onco Unit of Hospital University Mutua Terrassa (Barcelona, Spain) treating malignant tumors, focusing on results of unresectable pancreatic tumors treated with Ultrasound Guided High Intensity Focused Ultrasound (USgHIFU) hyperthermia ablation in combination with adjuvant chemotherapy. MATERIALS AND METHODS: From February 2008 to December 2013, we treated 140 malignant cases. Of those, 48 cases of unresectable pancreatic tumors were treated from March 2010 to December 2013, and the first 43 were included in the analysis. All the 43 cases (29 cases of stage III and 14 cases of stage IV) were treated with systemic chemotherapy. Clinical responses (thermical ablation achieved) were measured by image techniques, and complications were also recorded and analyzed. RESULTS: The majority of the 140 cases treated at our HIFU center were pancreatic and liver tumors, among which 43 cases of pancreatic tumors were analyzed. Clinical responses (ablation obtained) were observed in 82% of the cases, and the responses lasted at 8 weeks post-procedure. We obtained 11 complete responses (25%) at the end of the combined treatment, nine from stage III patients and two from stage IV patients. Major complications included severe pancreatitis with GI bleeding (1), and skin burning of grade III that required plastic surgery (2). The median survival was 13 months (6 months-2.7 years). No deaths were registered during the course of the treatment. CONCLUSIONS: HIFU is a potentially effective and safe modality for the treatment of malignant tumors. HIFU proves to have a survival advantage in treating unresectable pancreatic cancer.
Authors: Dobromir Dimitrov; Holger M Strunk; Milka Marinova; Hyuliya Feradova; Maria A Gonzalez-Carmona; Rupert Conrad; Tolga Tonguc; Marcus Thudium; Marc U Becher; Zhou Kun; Grigor Gorchev; Slavcho Tomov; Christian P Strassburg; Ulrike Attenberger; Hans H Schild Journal: Eur Radiol Date: 2021-01-23 Impact factor: 5.315
Authors: Matthew S Adams; Vasant A Salgaonkar; Juan Plata-Camargo; Peter D Jones; Aurea Pascal-Tenorio; Hsin-Yu Chen; Donna M Bouley; Graham Sommer; Kim Butts Pauly; Chris J Diederich Journal: Med Phys Date: 2016-07 Impact factor: 4.071
Authors: Anne Sailer; Pejman Ghanouni; George R Schade; Alessandro Napoli; Joan Vidal-Jove; Steven S Raman; Mishal Mendiratta-Lala; Sangeet Ghai; Andre Abreu; Karthik M Sundaram; Antonio Westphalen; Sandeep Arora Journal: Radiographics Date: 2022-10 Impact factor: 6.312
Authors: Matthew S Adams; Serena J Scott; Vasant A Salgaonkar; Graham Sommer; Chris J Diederich Journal: Int J Hyperthermia Date: 2016-01-21 Impact factor: 3.914
Authors: Milka Marinova; Maximilian Rauch; Martin Mücke; Roman Rolke; Maria A Gonzalez-Carmona; Jana Henseler; Henning Cuhls; Lukas Radbruch; Christian P Strassburg; Lian Zhang; Hans H Schild; Holger M Strunk Journal: Eur Radiol Date: 2016-02-17 Impact factor: 5.315
Authors: Andrew L Coveler; Jonathan Mizrahi; Bory Eastman; Smith Jim Apisarnthanarax; Shalini Dalal; Terry McNearney; Shubham Pant Journal: Oncologist Date: 2021-05-12